Rohit Sahai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Rohit Sahai has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Kalyan Mitra
CSIR-Central Drug Research Institute
2 shared publications Mayank Maheshwari
Division of Cancer Biology, CSIR-Central Drug Research Institute (CDRI), Lucknow, 226031, India
2 shared publicationsAkhilesh Singh
Biochemistry Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India
1 shared publicationDeepa Gandhi
Biochemistry Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India
1 shared publicationDipak Datta
Biochemistry Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India
1 shared publicationJayanta Sarkar
Division of Cancer Biology, CSIR-Central Drug Research Institute (CDRI), Lucknow, 226031, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
1 shared publication
Latest Publications
- 24 March 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 759, 151698
Ormeloxifene induces mitochondrial fission-mediated pro-death autophagy in colon cancer cells
- 24 March 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 759, 151698
Ormeloxifene induces mitochondrial fission-mediated pro-death autophagy in colon cancer cells
- Open Access
- 13 March 2020
- Published by Wiley in Cell Proliferation
- Vol. 53 (4) , e12749
Microtubule disrupting agent‐mediated inhibition of cancer cell growth is associated with blockade of autophagic flux and simultaneous induction of apoptosis
Objectives: Given that autophagy inhibition is a feasible way to enhance sensitivity of cancer cells towards chemotherapeutic agents, identifying potent autophagy inhibitor has obvious clinical relevance. Here, we investigated ability of TN‐16, a microtubule disrupting agent, on modulation of autophagic flux and its significance in promoting in vitro and in vivo cancer cell death.Materials and methods: The effect of TN‐16 on cancer cell proliferation, cell division, autophagic process and apoptotic signalling was assessed by various biochemical (Western blot and SRB assay), morphological (TEM, SEM, confocal microscopy) and flowcytometric assays. In vivo anti‐tumour efficacy of TN‐16 was investigated in syngeneic mouse model of breast cancer.Results: TN‐16 inhibited cancer cell proliferation by impairing late‐stage autophagy and induction of apoptosis. Inhibition of autophagic flux was demonstrated by accumulation of autophagy‐specific substrate p62 and lack of additional LC3‐II turnover in the presence of lysosomotropic agent. The effect was validated by confocal micrographs showing diminished autophagosome‐lysosome fusion. Further studies revealed that TN‐16–mediated inhibition of autophagic flux promotes apoptotic cell death. Consistent with in vitro data, results of our in vivo study revealed that TN‐16–mediated tumour growth suppression is associated with blockade of autophagic flux and enhanced apoptosis.Conclusions: Our data signify that TN‐16 is a potent autophagy flux inhibitor and might be suitable for (pre‐) clinical use as standard inhibitor of autophagy with anti‐cancer activity.
- 13 March 2020
- Published by Wiley in Cell Proliferation
- Vol. 53 (4) , e12749
Open AccessMicrotubule disrupting agent‐mediated inhibition of cancer cell growth is associated with blockade of autophagic flux and simultaneous induction of apoptosis
Objectives: Given that autophagy inhibition is a feasible way to enhance sensitivity of cancer cells towards chemotherapeutic agents, identifying potent autophagy inhibitor has obvious clinical relevance. Here, we investigated ability of TN‐16, a microtubule disrupting agent, on modulation of autophagic flux and its significance in promoting in vitro and in vivo cancer cell death.Materials and methods: The effect of TN‐16 on cancer cell proliferation, cell division, autophagic process and apoptotic signalling was assessed by various biochemical (Western blot and SRB assay), morphological (TEM, SEM, confocal microscopy) and flowcytometric assays. In vivo anti‐tumour efficacy of TN‐16 was investigated in syngeneic mouse model of breast cancer.Results: TN‐16 inhibited cancer cell proliferation by impairing late‐stage autophagy and induction of apoptosis. Inhibition of autophagic flux was demonstrated by accumulation of autophagy‐specific substrate p62 and lack of additional LC3‐II turnover in the presence of lysosomotropic agent. The effect was validated by confocal micrographs showing diminished autophagosome‐lysosome fusion. Further studies revealed that TN‐16–mediated inhibition of autophagic flux promotes apoptotic cell death. Consistent with in vitro data, results of our in vivo study revealed that TN‐16–mediated tumour growth suppression is associated with blockade of autophagic flux and enhanced apoptosis.Conclusions: Our data signify that TN‐16 is a potent autophagy flux inhibitor and might be suitable for (pre‐) clinical use as standard inhibitor of autophagy with anti‐cancer activity.
- 13 November 2017
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 53 (97) , 13079-13082
A short non-cytotoxic antimicrobial peptide designed from Aβ 29-40 adopts a nanostructure and shows in vivo anti-endotoxin activity
A schematic presentation of the plausible mechanism of antimicrobial activities of Aβ 29-40 -V2 and Aβ 29-40 -V4.
- 13 November 2017
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 53 (97) , 13079-13082
A short non-cytotoxic antimicrobial peptide designed from Aβ 29-40 adopts a nanostructure and shows in vivo anti-endotoxin activity
A schematic presentation of the plausible mechanism of antimicrobial activities of Aβ 29-40 -V2 and Aβ 29-40 -V4.